(Q40409913)

20 September 2017

title

Ambrisentan for pulmonary arterial hypertension (English)

1 reference

20 September 2017

Lewis J Rubin

1

1 reference

20 September 2017

Christopher Dufton

series ordinal

2

1 reference

20 September 2017

Michael J Gerber

series ordinal

3

1 reference

20 September 2017

publication date

1 July 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

1

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

425-432

1 reference

Clinical classification of pulmonary hypertension.

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Diagnosis and differential assessment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Treprostinil therapy for pulmonary artery hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Endothelin receptor is coupled to phospholipase C via a pertussis toxin-insensitive guanine nucleotide-binding regulatory protein in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Possible role of endothelin in endothelial regulation of vascular tone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Endothelin receptor antagonists in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Bosentan for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Relationship of serum antioxidants to asthma prevalence in youth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.1.4.425

21 January 2018

Identifiers

DOI

10.2217/14796678.1.4.425

1 reference

20 September 2017

1 reference